Lombard Odier Asset Management Switzerland SA Lowers Stock Position in Edwards Lifesciences Corporation $EW

Lombard Odier Asset Management Switzerland SA trimmed its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 53.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,594 shares of the medical research company’s stock after selling 7,458 shares during the quarter. Lombard Odier Asset Management Switzerland SA’s holdings in Edwards Lifesciences were worth $528,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $266,000. NewEdge Advisors LLC boosted its stake in shares of Edwards Lifesciences by 8.1% during the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock worth $2,787,000 after buying an additional 2,665 shares during the period. Sei Investments Co. grew its holdings in shares of Edwards Lifesciences by 16.7% during the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock worth $32,285,000 after buying an additional 58,988 shares during the last quarter. Squarepoint Ops LLC grew its holdings in shares of Edwards Lifesciences by 277.7% during the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after buying an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina increased its position in Edwards Lifesciences by 0.4% in the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after acquiring an additional 1,065 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on EW. Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Citigroup upped their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Evercore reaffirmed an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a report on Monday, July 6th. Finally, Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $87.00 to $101.00 in a research report on Friday, July 24th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.

Insiders Place Their Bets

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $83.01, for a total transaction of $84,587.19. Following the sale, the vice president owned 33,934 shares in the company, valued at $2,816,861.34. The trade was a 2.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 45,577 shares of company stock worth $3,855,527. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $83.69 on Wednesday. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The company has a 50-day moving average price of $87.77 and a 200 day moving average price of $83.85. The company has a market cap of $48.19 billion, a P/E ratio of 48.10, a PEG ratio of 2.09 and a beta of 0.86. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.85% and a net margin of 15.43%.The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the prior year, the business posted $0.67 EPS. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts predict that Edwards Lifesciences Corporation will post 2.99 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.